23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
20. November 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a...
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
12. November 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second quarter...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
11. November 2024 17:30 ET
|
23andMe, Inc.
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all...
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
07. November 2024 17:54 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the...
23andMe to Report Q2 FY2025 Financial Results
07. November 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial...
23andMe Regains Compliance With Nasdaq Listing Requirements
30. Oktober 2024 17:00 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced that the...
23andMe Appoints Three New Independent Directors to Board
29. Oktober 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the...
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
17. Oktober 2024 16:05 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, released a powerful new feature that enables African American customers to...
23andMe Announces Completion of 1-for-20 Reverse Stock Split
16. Oktober 2024 08:15 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today the completion of the previously announced 1-for-20 reverse stock...
23andMe Announces 1-for-20 Reverse Stock Split
11. Oktober 2024 08:15 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today that the 1-for-20 reverse stock split of the Company’s Class A and...